Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314276 | 0.93 | SMN1; SMN2 (0.35) | ARG1ARG2SMN1; SMN2LTA4H | |
| SCHEMBL13730325 | 0.90 | SMN1; SMN2 (0.33) | ARG1ARG2SMN1; SMN2LTA4H | |
| SCHEMBL14472771 | 0.85 | — | — | |
| SCHEMBL12181288 | 0.80 | CHRM1 (0.33) | ARG1ARG2SMN1; SMN2 | |
| SCHEMBL13510862 | 0.79 | SMN1; SMN2 (0.35) | ARG1ARG2SMN1; SMN2 | |
| SCHEMBL421373 | 0.78 | ALDH1A1 (0.40) | SMN1; SMN2LTA4H | |
| SCHEMBL19102455 | 0.77 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL10074652 | 0.75 | CYP19A1 (0.35) | SMN1; SMN2 | |
| SCHEMBL12650302 | 0.75 | ALDH1A1 (0.32) | — | |
| SCHEMBL12181600 | 0.74 | SMN1; SMN2 (0.35) | ARG1ARG2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43612-E1 | Biodegradable poly(β-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110059172-A1 | THERAPEUTIC COMPOSITIONS | TZIANABOS ARTHUR | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059172-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, ACP1, TUBB3 | ARG1 63/4885ARG2 73/4885SMN1; SMN2 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.